Hair Thinning: Drugs That Cause It, Drugs That Treat It, and What Else Explains It

What Actually Causes Hair Thinning?

Hair thinning is not a single disease. It is a final common pathway shared by genetic predisposition, hormonal dysregulation, systemic illness, nutritional deficiency, and drug side effects. Before choosing a treatment, clinicians must identify which pathway is active, because applying minoxidil to iron-deficiency-driven shedding without correcting the ferritin level produces modest results at best.

The Hair Cycle and Why It Matters

Each follicle cycles through three phases: anagen (active growth, 2-7 years), catagen (brief regression, 2-3 weeks), and telogen (resting, 3 months). At any given moment, roughly 85-90% of scalp follicles are in anagen and 10-15% are in telogen. When an insult, whether a drug, fever, surgery, or crash diet, pushes too many follicles into telogen simultaneously, the result is diffuse shedding 2-3 months later. This is telogen effluvium.

Androgenetic alopecia (AGA) operates differently. Dihydrotestosterone (DHT) binds androgen receptors in genetically susceptible follicles, progressively miniaturizing them over years until they stop producing visible hair. Androgens and scalp DHT metabolism are reviewed in detail on PubMed.

Common Non-Drug Causes

• Thyroid dysfunction. Both hypothyroidism and hyperthyroidism disrupt the anagen-to-telogen ratio. A 2018 review in the Journal of Clinical Endocrinology and Metabolism confirmed thyroid hormone receptors are expressed on hair follicle keratinocytes. (PubMed)
• Iron deficiency. Serum ferritin below 30 ng/mL is consistently associated with telogen effluvium in premenopausal women. (PubMed)
• Polycystic ovary syndrome (PCOS). Androgen excess from PCOS accelerates follicular miniaturization in women with genetic susceptibility.
• Scalp disorders. Seborrheic dermatitis, tinea capitis, and lichen planopilaris each cause thinning through distinct inflammatory or infectious mechanisms.
• Physical or emotional stress. Major surgery, COVID-19 infection, and severe psychological stress are all documented triggers of acute telogen effluvium. A 2021 case series noted dramatic shedding 60-90 days post-COVID in a substantial proportion of patients. (PubMed)

Drugs That Cause Hair Thinning

Drug-induced alopecia is underreported. The mechanism is either anagen effluvium (the drug arrests active cell division in the follicle, as cytotoxic chemotherapy does) or telogen effluvium (the drug shifts follicles prematurely into resting phase). Recognizing the responsible agent and the timeline is the core diagnostic task.

Chemotherapy and Targeted Oncology Agents

Classic cytotoxic agents, including cyclophosphamide, doxorubicin, and paclitaxel, cause anagen effluvium in nearly 65-100% of patients. Hair loss begins 1-3 weeks after the first infusion and is typically complete within 1-2 months. The FDA label for cyclophosphamide explicitly lists alopecia as a very common adverse event. (FDA prescribing information, accessdata.fda.gov)

Newer targeted agents, including EGFR inhibitors such as erlotinib and some CDK4/6 inhibitors, cause a different pattern: diffuse thinning rather than complete loss, which can persist throughout therapy.

Cardiovascular Medications

Beta-blockers, particularly propranolol and metoprolol, are well-documented causes of telogen effluvium. The ACE inhibitor enalapril and the anticoagulant warfarin also appear on multiple case-series lists. Heparin-induced alopecia has been documented at high therapeutic doses used for more than 3 months. (PubMed)

Hormonal Therapies

This category is especially relevant for HealthRX patients.

• Oral contraceptives (OCs) with high androgenicity. Levonorgestrel-containing pills carry a higher androgenic index than desogestrel or norgestimate formulations. Women genetically predisposed to AGA may notice thinning during or after stopping an OC. Stopping itself triggers a "post-pill effluvium" 1-3 months later, even with low-androgen pills, due to the sudden withdrawal of estrogen support.
• Testosterone replacement therapy (TRT). Exogenous testosterone converts to DHT via 5-alpha reductase. Men and women using TRT may accelerate AGA if they carry susceptible follicle genotypes. (PubMed, androgen-alopecia pathway)
• Danazol. This synthetic androgen, used for endometriosis and hereditary angioedema, causes androgenic alopecia at therapeutic doses.
• Medroxyprogesterone acetate. Has moderate androgenic activity and appears in multiple alopecia case reports.

Retinoids

Isotretinoin (Accutane) for acne and acitretin for psoriasis both cause dose-dependent telogen effluvium. The mechanism involves disruption of follicular keratinization. Shedding is usually reversible after dose reduction or discontinuation, though recovery can take 6-9 months. (PubMed)

Psychotropic and Neurological Medications

Valproic acid is one of the most consistent culprits. A prospective study found alopecia in up to 24% of patients taking valproate for epilepsy. Lithium, carbamazepine, and some SSRIs, particularly fluoxetine and sertraline, appear in spontaneous adverse event databases, though causality is harder to establish. (PubMed, valproate)

Cholesterol-Lowering Agents

Statins, especially simvastatin and atorvastatin, have been associated with alopecia in post-marketing surveillance, but the absolute risk appears low and the association is not confirmed in large RCTs. Fibrates carry a similar low-level signal.

Table: Drug Classes and Their Alopecia Mechanisms

| Drug Class | Example Agents | Mechanism | Reversibility | |---|---|---|---| | Cytotoxic chemotherapy | Cyclophosphamide, paclitaxel | Anagen effluvium | Usually reverses post-treatment | | Beta-blockers | Propranolol, metoprolol | Telogen effluvium | Typically reverses in 3-6 months | | Retinoids | Isotretinoin, acitretin | Telogen effluvium | Reverses in 6-9 months | | Androgenic hormones | Danazol, TRT | DHT-mediated miniaturization | Partial; depends on genetics | | Anticoagulants | Heparin, warfarin | Telogen effluvium | Usually reverses | | Antiepileptics | Valproic acid | Telogen effluvium | Partially reverses | | Oral contraceptives | Levonorgestrel-OCs | Androgenic or post-pill effluvium | Usually reverses |

FDA-Approved Drugs That Treat Hair Thinning

Two medications hold FDA approval specifically for alopecia in the setting of androgenetic hair loss. Several others are used routinely off-label.

Minoxidil

Minoxidil was originally a vasodilator for hypertension. Topical 2% became FDA-approved for women's AGA in 1991; topical 5% was approved for men in 1997. The mechanism is not fully understood but appears to involve opening ATP-sensitive potassium channels in follicle cells, prolonging anagen and increasing follicle size.

Evidence: A 48-week RCT (N=393) comparing 5% minoxidil foam to vehicle showed a statistically significant increase in target area hair count (TAHC) at week 24 and week 48 (P<0.001). (PubMed)

Oral minoxidil at low doses (0.25-2.5 mg/day in women, 2.5-5 mg/day in men) is increasingly prescribed off-label for patients who cannot tolerate topical application. A 2021 retrospective study of 1,404 patients found 59% had a positive hair-density response at 6 months with oral minoxidil, with hypertrichosis as the most common side effect. (PubMed)

The American Academy of Dermatology guideline states: "Minoxidil 2% or 5% topical solution is recommended as a first-line treatment for both male and female androgenetic alopecia." (AAD, via NCBI bookshelf)

Finasteride

Finasteride inhibits type II 5-alpha reductase, reducing scalp DHT by approximately 60-70%. Propecia (1 mg) is FDA-approved for male AGA. Proscar (5 mg) is approved for benign prostatic hyperplasia but prescribed off-label for AGA.

Evidence: A 2-year RCT (N=1,553) published in the Journal of the American Academy of Dermatology showed 83% of men taking finasteride 1 mg maintained or increased hair count, versus 28% on placebo. (PubMed)

Finasteride is not FDA-approved for premenopausal women due to teratogenicity risk. It is prescribed off-label in postmenopausal women, sometimes at 2.5-5 mg/day. A Cochrane review of treatments for female-pattern hair loss noted evidence for finasteride in postmenopausal women is present but limited compared with the male data. (Cochrane Library)

Side effects: Sexual adverse effects, including decreased libido, ejaculatory dysfunction, and erectile dysfunction, are reported in roughly 2-4% of men in clinical trials. Post-finasteride syndrome (persistent sexual and neuropsychiatric symptoms after stopping the drug) remains under investigation. The FDA added a label update in 2012 to include persistent side effects. (FDA drug safety communication)

Off-Label and Emerging Treatments

Spironolactone for Women

Spironolactone is an aldosterone antagonist with anti-androgenic properties. At doses of 100-200 mg/day, it is widely used off-label for female AGA and PCOS-related hair loss. A 2015 retrospective study (N=80) in the Journal of the American Academy of Dermatology found 44% of women showed improvement in hair density after 12 months. (PubMed)

Monitoring requirements include serum potassium at 4-6 weeks (risk of hyperkalemia), blood pressure, and menstrual changes.

Dutasteride

Dutasteride inhibits both type I and type II 5-alpha reductase, reducing scalp DHT by approximately 90% compared with finasteride's 60-70%. It is FDA-approved for benign prostatic hyperplasia (as Avodart 0.5 mg) and is prescribed off-label for AGA, particularly in patients who have had an inadequate response to finasteride. A 24-week RCT (N=416) demonstrated significantly greater hair count improvement with dutasteride 0.5 mg vs. Finasteride 1 mg (P<0.001). (PubMed)

Platelet-Rich Plasma (PRP)

PRP involves concentrating autologous growth factors from the patient's own blood and injecting them into the scalp. A 2019 meta-analysis of 19 RCTs (N=460 patients) published in the Journal of the American Academy of Dermatology found statistically significant improvements in hair density and hair diameter versus control. (PubMed)

Results vary substantially by preparation technique, injection protocol, and number of sessions.

Low-Level Laser Therapy (LLLT)

The FDA has cleared several LLLT devices (laser combs and caps) for both male and female AGA under the 510(k) pathway. A 26-week sham-controlled RCT (N=128) showed a 39% increase in mean hair count in the LLLT group versus 0% in sham controls. (PubMed)

JAK Inhibitors for Alopecia Areata

Baricitinib (Olumiant) received FDA approval in June 2022 specifically for severe alopecia areata. It is not indicated for androgenetic alopecia. The key BRAVE-AA1 and BRAVE-AA2 trials (combined N=1,200) showed 35-40% of patients achieved SALT score improvement of 80 or more after 36 weeks. (FDA approval announcement) (PubMed, BRAVE-AA trials)

Ritlecitinib (Litfulo) was approved by the FDA in June 2023 for severe alopecia areata in patients 12 years and older, making it the first approved for adolescents. (FDA press announcement)

Diagnosing Hair Thinning: The Clinical Workup

History and Physical

The first question is pattern. Diffuse loss points toward telogen effluvium or nutritional cause. Frontotemporal or vertex recession points toward AGA. Patchy, well-demarcated loss points toward alopecia areata or tinea capitis. Scarring on the scalp surface suggests a cicatricial alopecia (lichen planopilaris, discoid lupus), which requires dermatology referral because follicle destruction is permanent.

A thorough medication review is mandatory. Any drug started 2-4 months before the onset of shedding is a suspect.

Laboratory Evaluation

The following panel is standard for diffuse hair thinning with no obvious cause:

• TSH and free T4 (thyroid)
• Serum ferritin (target above 70 ng/mL in women with hair loss, per some expert guidelines)
• Complete blood count
• Comprehensive metabolic panel
• DHEA-S and total testosterone (both sexes)
• Prolactin if menstrual irregularity is present
• 25-OH vitamin D (deficiency is associated with alopecia areata; evidence for AGA is weaker)
• Zinc (rarely deficient but correctable)

Scalp Biopsy and Dermoscopy

Dermoscopy (trichoscopy) allows the clinician to examine follicular units non-invasively. Yellow dots suggest follicular keratosis in alopecia areata; peripilar casts and anisotrichosis suggest AGA. A 4-mm punch biopsy with horizontal sectioning is the gold standard when the diagnosis remains unclear after clinical and lab evaluation. (PubMed, trichoscopy review)

Hair Thinning in the Context of Hormone Therapy

Patients on TRT, HRT, or GLP-1 agonist therapy deserve a specific decision framework for hair thinning because each therapy intersects differently with follicle biology.

TRT in men: Baseline scalp DHT sensitivity determines risk. Men with first-degree relatives who experienced significant AGA before age 40 carry higher risk. Options include co-prescribing finasteride 1 mg daily, using topical DHT-blocking shampoos (ketoconazole 2% has modest supportive data), and applying topical minoxidil 5% to the vertex.

TRT in women (low-dose testosterone for libido/energy): Even physiologic-range testosterone supplementation can trigger or accelerate thinning in genetically susceptible women. Monitoring should include visual scalp assessment at every 6-month follow-up. If thinning appears, spironolactone 50-100 mg/day may offset the androgenic stimulus.

Estrogen/progesterone HRT in postmenopausal women: Estrogen generally has a protective effect on hair follicles by prolonging anagen. Switching from a progestin with high androgenic activity (norethindrone acetate) to one with low androgenic activity (micronized progesterone or dydrogesterone) may reduce shedding in susceptible women.

GLP-1 agonists (semaglutide, tirzepatide): Rapid weight loss, defined as more than 1-1.5 kg/week, is a recognized trigger for telogen effluvium. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks. A subset of patients in clinical practice report increased shedding at the 3-6 month mark, consistent with the physiologic timeline of acute weight-loss-triggered effluvium. The shedding typically resolves as weight loss rate slows, without any change to the GLP-1 regimen. Adequate protein intake (at minimum 1.2 g/kg ideal body weight per day) and maintained ferritin levels help mitigate the degree of shedding. (STEP-1 trial, NEJM)

When to Refer and When to Start Treatment Empirically

Hair thinning that has been present for less than 6 months with a clear identifiable trigger (new medication, major surgery, COVID-19 infection, rapid weight loss) can reasonably be managed conservatively. Correct any deficiencies, remove the offending drug where clinically safe, and reassess at 3 months.

Hair thinning lasting more than 6 months, or thinning with scalp symptoms (itching, pain, burning), visible scalp surface changes, or a positive family history of early hair loss warrants formal dermatology evaluation.

The American Academy of Dermatology specifically recommends starting minoxidil without delay in confirmed AGA because earlier treatment preserves more follicles. There is no benefit to waiting once the diagnosis is established. Serum ferritin should be at or above 70 ng/mL before concluding that minoxidil monotherapy has failed in a woman.